**SUPPLEMENT: Survey results**

**Title:**

**Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS).**

**Part II: Attack therapy and long-term management**

**Authors:**

Tania Kümpfel1, Katrin Giglhuber2, Orhan Aktas3, Ilya Ayzenberg4, Judith Bellmann-Strobl5,6,7,8, Vivien Häußler9, Joachim Havla1, Kerstin Hellwig4, Martin W. Hümmert10, Sven Jarius11, Ingo Kleiter4,12, Luisa Klotz13, Markus Krumbholz14,15,16, Friedemann Paul5,6,7,8, Marius Ringelstein3,17, Klemens Ruprecht5, Makbule Senel18, Jan-Patrick Stellmann9,19,20, Florian Then Bergh21, Corinna Trebst11, Hayrettin Tumani19, Clemens Warnke22, Brigitte Wildemann12, Achim Berthele2; on behalf of the Neuromyelitis Optica Study Group (NEMOS)

1 Institute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität

München, Munich, Germany

2 Department of Neurology, School of Medicine, Technical University Munich, Klinikum rechts

der Isar, Munich, Germany

3 Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf,

Germany

4 Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany

5 Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie

Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

6 Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center

for Molecular Medicine in the Helmholtz Association and Charité – Universitätsmedizin Berlin,

Germany

7 Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin,

Germany

8 NeuroCure Clinical Research Center, Charité Universitätsmedizin Berlin, corporate member

of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health,

and Max Delbrück Center for Molecular Medicine, Berlin, Germany

9 Department of Neurology and Institute of Neuroimmunology and MS (INIMS), University

Medical Center Hamburg-Eppendorf, Hamburg, Germany

10 Department of Neurology, Hannover Medical School, Hannover, Germany

11 Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg,

Heidelberg, Germany

12 Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke,

Berg, Germany

13 Department of Neurology with Institute of Translational Neurology, University of Münster,

Münster, Germany

14 Department of Neurology and Pain Treatment, Immanuel Klinik Rüdersdorf, University

Hospital of the Brandenburg Medical School Theodor Fontane, Rüdersdorf bei Berlin, Germany

15 Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane,

Rüdersdorf bei Berlin, Germany

16 Department of Neurology & Stroke, University Hospital of Tübingen, Tübingen, Germany

17 Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich

Heine University Düsseldorf, Düsseldorf, Germany

18 Department of Neurology, University of Ulm, Ulm, Germany

19 APHM, Hopital de la Timone, CEMEREM, Marseille, France

20 Aix Marseille Univ, CNRS, CRMBM, Marseille, France

21 Department of Neurology, University of Leipzig, Leipzig, Germany

22 Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

\* Corresponding authors:

Tania Kümpfel: Tania.Kuempfel@med.uni-muenchen.de

Achim Berthele: achim.berthele@tum.de

**Survey results**

Results of the DELPHI survey for the recommendations A1-B29. An approval of >75% was rated as consent.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Recommendation | Number of votes | Number of approvals | Number of rejections | Approval [%] |
| A1 | 24 | 24 | 0 | 100 |
| A2 | 24 | 22 | 2 | 92 |
| A3 | 24 | 24 | 0 | 100 |
| A4 | 24 | 22 | 2 | 92 |
| A5 | 24 | 22 | 2 | 92 |
| A6 | 24 | 23 | 1 | 96 |
| B1 | 24 | 24 | 0 | 100 |
| B2 | 24 | 21 | 3 | 88 |
| B3 | 24 | 22 | 2 | 92 |
| B4 | 24 | 24 | 0 | 100 |
| B5 | 24 | 22 | 2 | 92 |
| B6 | 24 | 23 | 1 | 96 |
| B7 | 24 | 24 | 0 | 100 |
| B8 | 24 | 23 | 1 | 96 |
| B9 | 24 | 24 | 0 | 100 |
| B10 | 24 | 22 | 2 | 92 |
| B11 | 24 | 24 | 0 | 100 |
| B12 | 24 | 23 | 1 | 96 |
| B13 | 24 | 23 | 1 | 96 |
| B14 | 24 | 23 | 1 | 96 |
| B15 | 24 | 22 | 2 | 92 |
| B16 | 24 | 21 | 3 | 88 |
| B17 | 24 | 22 | 2 | 92 |
| B18 | 24 | 23 | 1 | 96 |
| B19 | 24 | 24 | 0 | 100 |
| B20 | 24 | 24 | 0 | 100 |
| B21 | 24 | 19 | 5 | 79 |
| B22 | 24 | 24 | 0 | 100 |
| B23 | 24 | 23 | 1 | 96 |
| B24 | 24 | 23 | 1 | 96 |
| B25 | 24 | 20 | 4 | 83 |
| B26 | 24 | 24 | 0 | 100 |
| B27 | 24 | 22 | 2 | 92 |
| B28 | 24 | 23 | 1 | 96 |
| B29 | 24 | 23 | 1 | 96 |

The implementation of ravulizumab in the recommendations was voted additionally and separately in April 2023 after the CHMP of the EMA recommended approval for ravulizumab for treatment of AQP-4-IgG positive NMOSD in April 2023. 23/24 authors consented (96%) to include ravulizumab in the manuscript and recommendations.